Article
Dermatology
Akimichi Morita, Yukari Okubo, Yoji Morisaki, Hitoe Torisu-Itakura, Yoshinori Umezawa
Summary: This study assessed the efficacy and safety of ixekizumab in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. The results indicated that continuous dosing of ixekizumab every 2 weeks was effective and safe for treating these patients, showing improvements in symptoms with a well-tolerated safety profile.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Emanuele Trovato, Corinne Orsini, Filomena Russo, Giulio Cortonesi, Pietro Rubegni
Summary: Erythodermic psoriasis is a rare subset of psoriasis considered a dermatologic emergency, with limited clinical evidence and unknown pathogenesis. In addition to conventional therapies, studies suggest that biologics may be a new treatment option.
DERMATOLOGIC THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Huixia Wang, Sijia Wang, Liang Li, Xiuying Wang, Chengfei Liu, Mei Lu, Yumin Xia, Yale Liu
Summary: The TWEAK cytokine plays a role in the pathogenesis of psoriasis, showing significant correlation with IL-17A, IFN-gamma, and IL-36 gamma, but not with IL-22.
Article
Dermatology
Yukari Okubo, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Summary: This study reports the efficacy and safety of certolizumab pegol (CZP) in Japanese patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The results showed that CZP treatment improved the signs and symptoms of GPP and EP, and the improvements were maintained throughout the treatment period.
DERMATOLOGY AND THERAPY
(2022)
Article
Medicine, General & Internal
Gianluca Avallone, Carlo Alberto Maronese, Giulia Murgia, Carlo Giovanni Carrera, Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo, Silvia Alberti-Violetti, Pietro Quaglino, Simone Ribero, Angelo Valerio Marzano
Summary: This study aimed to compare the efficacy of IL-17 and IL-23 inhibitors in treating pustular and erythrodermic psoriasis. The results showed that IL-17 inhibitors had higher effectiveness in treating these conditions, while the efficacy of IL-23 inhibitors remains unknown.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Chika Ohata, Noriko Tsuruta, Kentaro Yonekura, Yuko Higashi, Kanami Saito, Eri Katayama, Shinichi Imafuku
Summary: Generalized pustular psoriasis (GPP) is a rare and severe subtype of psoriasis that predominantly affects females with lower body mass index and lesser rates of alcohol consumption. The study identified different types of GPP, age at onset, and precipitating factors, shedding light on the demographics and characteristics of patients with GPP.
JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Keiichi Yamanaka, Yukari Okubo, Ikuko Yasuda, Nobuo Saito, Izabella Messina, Akimichi Morita
Summary: Risankizumab has demonstrated clinically meaningful efficacy and durable efficacy with a favorable long-term safety profile in Japanese patients with GPP or EP.
JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Alexander Egeberg, Lars Erik Kristensen, Ron Vender, Shirin Zaheri, Celine EL Baou, Gaia Gallo, Elisabeth Riedl, Christopher Schuster
Summary: This study evaluates the long-term effects of ixekizumab treatment on nail psoriasis, showing that continuous treatment can improve and clear nail psoriasis regardless of the severity at baseline.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Dermatology
April Armstrong, David Amato, William Huster, Clement Ojeh, Abby S. Van Voorhees
Summary: The study found that ixekizumab, an interleukin 17 inhibitor, demonstrated high efficacy in treating patients with plaque psoriasis, achieving the treatment targets defined by NPF.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Dermatology
Elisabeth Riedl, Ulrich Mrowietz, Julie B. Hill, Christophe Sapin, Richard Warren
Summary: This post-hoc subgroup analysis compared the efficacy of Ixekizumab and Etanercept in patients with moderate-to-severe psoriasis selected into groups defined by original reimbursement criteria from eight European countries. The results showed that Ixekizumab had higher treatment response rates than Etanercept, regardless of meeting reimbursement criteria, in terms of PASI 75/90/100 response rates and DLQI (0,1) response rates.
JOURNAL OF DRUGS IN DERMATOLOGY
(2022)
Article
Dermatology
Koji Kamiya, Mamitaro Ohtsuki
Summary: The Japanese Society for Psoriasis Research has conducted epidemiological surveys on patients with pustular psoriasis in Japan every year since 2017. This study provides recent epidemiological analysis and treatment trends of patients with pustular psoriasis in Japan, revealing patient characteristics and the usage of oral medications and biologics. The findings offer valuable information for understanding pustular psoriasis in Japan.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Katherine C. Awh, Christian A. Albornoz, Kumar S. Nadhan, Meghan Buckley, Steven R. Feldman, M. Anthony Albornoz
Summary: Despite concerns about life-threatening complications, orally administered glucocorticoids are frequently used for psoriasis treatment. Severe generalized pustular psoriasis and erythrodermic psoriasis, the potential risks, are not commonly seen. Younger dermatologists are more likely to prescribe oral glucocorticoids for psoriasis.
JOURNAL OF DRUGS IN DERMATOLOGY
(2022)
Article
Dermatology
Tsen-Fang Tsai, Min Zheng, Yangfeng Ding, Zhiqi Song, Quanzhong Liu, Ying Chen, Hanzhao Hu, Jinhua Xu
Summary: This study aims to investigate the efficacy and safety of spesolimab, a new drug for generalized pustular psoriasis, in Chinese patients.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Akimichi Morita, Nirali Kotowsky, Ran Gao, Reiko Shimizu, Yukari Okubo
Summary: Generalized pustular psoriasis (GPP) is a rare and severe systemic, neutrophilic skin disease. This study in Japan showed that patients with GPP have a higher burden of illness compared to those with plaque psoriasis, including higher prevalence of comorbidities, different medication use, and increased healthcare resource utilization.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Martina Burlando, Ilaria Salvi, Andrea Paravisi, Emanuele Cozzani, Aurora Parodi
Summary: Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening disease. Treatment with ixekizumab can rapidly improve the condition of GPP patients, and long-term treatment for 2 years has shown no adverse events.
CASE REPORTS IN DERMATOLOGY
(2022)